1,4-二氧螺环[4,5]癸烷 | 177-10-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1,4-二氧螺环[4,5]癸烷
• 中文别名: 1,4-二氧杂螺[4.5]癸烷；2,2-五亚甲基-1,3-二氧戊环
• 英文名称: 1,3-dioxolane-2-spirocyclohexane
• 英文别名: 1,4-dioxaspiro[4.5]decane；cyclohexanone ethylene ketal；cyclohexanone ethylene acetal；2,2-pentamethylene-1,3-dioxolane
• CAS: 177-10-6
• 化学式: C₈H₁₄O₂
• mdl: MFCD00005409
• 分子量: 142.198
• InChiKey: GZGPRZYZKBQPBQ-UHFFFAOYSA-N

物化性质

• 熔点：
  176-180 °C
• 沸点：
  73 °C16 mm Hg(lit.)
• 密度：
  1.028 g/mL at 25 °C(lit.)
• 闪点：
  156 °F

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 安全说明：
  S24/25
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存放于惰性气体中，并避免接触湿气（否则可能导致分解）。

SDS

Name:	2 2-Pentamethylene-1 3-Dioxolane 99% Material Safety Data Sheet
Synonym:	Cyclohexanone Ethylene Acetal; Cyclohexanone Ethylene Ketal; 1,4-Dioxaspiro(4.5)Decane
CAS:	177-10-6

Section 1 - Chemical Product MSDS Name:2 2-Pentamethylene-1 3-Dioxolane 99% Material Safety Data Sheet
Synonym:Cyclohexanone Ethylene Acetal; Cyclohexanone Ethylene Ketal; 1,4-Dioxaspiro(4.5)Decane

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
177-10-6	2,2-Pentamethylene-1,3-Dioxolane	99%	205-867-0

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. May cause chemical conjunctivitis and corneal damage.
Skin:
May cause irritation and dermatitis. May cause cyanosis of the extremities.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Aspiration may lead to pulmonary edema. Inhalation at high concentrations may cause CNS depression and asphixiation.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use water spray to keep fire-exposed containers cool. Combustible liquid.
Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Containers may explode when heated.
Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray to cool fire-exposed containers. Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or alcohol-resistant foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Remove all sources of ignition. Use a spark-proof tool. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use only in a well-ventilated area. Avoid contact with eyes, skin, and clothing. Empty containers retain product residue, (liquid and/or vapor), and can be dangerous. Keep container tightly closed. Keep away from heat, sparks and flame. Avoid ingestion and inhalation. Do not pressurize, cut, weld, braze, solder, drill, grind, or expose empty containers to heat, sparks or open flames.
Storage:
Keep away from sources of ignition. Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 177-10-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: clear, colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 73 deg C @ 16.00mm Hg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: 69 deg C ( 156.20 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: 1.0280g/cm3
Molecular Formula: C8H14O2
Molecular Weight: 142.20

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, ignition sources, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 177-10-6: JH2800000 LD50/LC50:
Not available.
Carcinogenicity:
2,2-Pentamethylene-1,3-Dioxolane - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 177-10-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 177-10-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 177-10-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,4-二氧螺环[4,5]癸烷 在 polyaniline-sulfate salt 、 水 作用下， 反应 0.75h， 以95%的产率得到环己酮
  参考文献：
  名称：

  Polyaniline-Supported Sulfuric Acid Salt as a Powerful Catalyst for the Protection and Deprotection of Carbonyl Compounds

  摘要：

  结构不同的羰基化合物在干燥甲苯中以聚苯胺硫酸盐为催化剂，优异地转化为相应的环状缩醛。随后，演示了在水相介质中的有用脱缩醛反应。还证明了羰基化合物的化学选择性保护。聚苯胺硫酸盐的优势在于制备和操作简便、稳定性、可重复使用性和活性。

  DOI：

  10.1055/s-2003-41412
• 作为产物：
  描述：

  2-<(cyclohex-1-enyl)oxy>ethanol 在 N-溴代丁二酰亚胺(NBS) 、 溶剂黄146 、 三乙胺 作用下， 反应 34.17h， 生成 1,4-二氧螺环[4,5]癸烷
  参考文献：
  名称：

  由羟烷基烯醇醚形成立体缩酮，这是一种立体电子控制的内触发环化过程†

  摘要：

  在1当量的存在下，酸催化的环状缩酮的形成与一系列羟烷基环状烯醇醚的水解反应。H 2 O的生成，酸催化的环状缩酮的形成（与上述缩酮相同）与在4当量存在的情况下一系列混合的戊4烯基羟烷基缩酮与N-溴代琥珀酰亚胺的甲醇分解反应。MeOH导致相同的结果：分子内环化过程发生的速率与分子间H 2 O或MeOH攻击的速率相似，而与环化形成的环（五元，六元或七元）的大小无关。这些结果可以通过以下事实来解释，即由于立体电子效应而对sp 2施加了扭转应变杂化的O原子，随着羟烷基链长度的增加，环化活化焓降低（环化的容易度：7> 6> 5），而熵因子有利于环化反应的逆向（环化的容易度：5> 6） > 7）。使用半经验哈密​​顿量AM1检查了各种反应途径，获得的结果证实，大环的形成在焓上比导致小环的环化过程更受青睐（环化的容易程度：7> 6> 5）。

  DOI：

  10.1002/hlca.19960790106

文献信息

• Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
  申请人：John Varghese

  公开号：US20060014737A1

  公开（公告）日：2006-01-19

  The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  这项发明涉及新型化合物和治疗与淀粉样变性相关的疾病、紊乱和症状的方法。淀粉样变性指与A-beta蛋白异常沉积相关的一系列疾病、紊乱和症状。
• Stereoselective Hydrosilylation of Enals and Enones Catalysed by Palladium Nanoparticles
  作者：Meryem Benohoud、Sakari Tuokko、Petri M. Pihko

  DOI：10.1002/chem.201100655

  日期：2011.7.18

  A highly versatile and efficient hydrosilylation method by palladium nanoparticle catalysis allows the direct and chemoselective synthesis of 1) enolsilanes of high isomeric purity, 2) saturated aldehydes or ketones, or 3) the corresponding saturated acetals from α,β‐unsaturated aldehydes or ketones. The choice of the product is determined by simply switching the solvent from THF to mixtures of THF/water

  通过钯纳米粒子催化的高度通用和高效的氢化硅烷化方法可以直接和化学选择性地合成1）高异构纯度的烯醇硅烷，2）饱和醛或酮或3）由α，β-不饱和醛或酮相应的饱和缩醛。通过简单地将溶剂从THF切换为THF /水或THF /醇的混合物来确定产品的选择。
• 2,4,4,6-Tetrabromo-2,5-cyclohexadienone (TABCO), N-Bromosuccinimide (NBS) and Bromine as Efficient Catalysts for Dithioacetalization and Oxathioacetalization of Carbonyl Compounds and Transdithioacetalization Reactions
  作者：Nasser Iranpoor、Habib Firouzabadi、Hamid Reza Shaterian、M. A. Zolfigol

  DOI：10.1080/10426500211712

  日期：2002.5.1

  6-tetrabromo-2,5-cyclohexadienone (TABCO), N-bromosuccinimide (NBS), and bromine as efficient catalysts for conversion of carbonyl compounds to their cyclic and acyclic dithioacetals and 1,3-oxathiolanes under mild reaction conditions are described. These catalysts are also used for efficient transdithioacetalization of acetals, diacetals, ketals, acylals, enamines, hydrazones, and oximes with high

  使用 2,4,4,6-四溴-2,5-环己二烯酮 (TABCO)、N-溴代琥珀酰亚胺 (NBS) 和溴作为有效催化剂将羰基化合物转化为环状和无环二硫缩醛和 1,3-描述了在温和反应条件下的硫杂环戊烷。这些催化剂还用于在硫醇存在下以高产率有效地将缩醛、二缩醛、缩酮、酰基、烯胺、腙和肟转二硫缩醛。
• [EN] NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS THIOPHÉNYLAMIDE BICYCLIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013189841A1

  公开（公告）日：2013-12-27

  The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A, E and n are as described herein, compositions including the compounds and use thereof as fatty-acid binding protein (FABP) 4/5 inhibitors in the treatment of e.g. type 2 diabetes, atherosclerosis or cancer.

  这项发明提供了具有一般式（I）的新化合物，其中R1、R2、R3、R4、R5、R6、R7、A、E和n如本文所述，包括这些化合物的组合物以及将其用作脂肪酸结合蛋白（FABP）4/5抑制剂，用于治疗例如2型糖尿病、动脉粥样硬化或癌症。
• THIAZOLYL-DIHYDRO-CHINAZOLINE
  申请人：Brandl Trixi

  公开号：US20070238746A1

  公开（公告）日：2007-10-11

  Disclosed are compounds of general formula (I), wherein the groups A, R 1 , R 2 , R a and R b have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.

  揭示了一般式(I)的化合物， 其中，基团A，R1，R2，Ra和Rb具有权利要求和说明中给定的含义，其互变异构体，拉克酸盐，对映体，非对映体和它们的混合物，以及可选择的药理学上可接受的酸加盐，溶剂合物和水合物，以及制备这些噻唑基-二氢喹唑啉并将其用作药物组合物的方法。

表征谱图